Gordon Carl L's Form 4 filing
Theseus Pharmaceuticals, Inc. (THRX) · filed Nov 9, 2022
- Accession no.
- 0000947871-22-001158
- Filed
- Nov 9, 2022
- Trade date
- Nov 7, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $1.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gordon Carl LCIK 0001282930 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2022 | Common Stock | PPurchaseAcquired | +192,000 | $5.21F1 | +$1,000,320 | 16,734,518 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of the shares of the Issuer's common stock ("Shares") purchased, ranging from a low of $5.08 to a high of $5.52 per Share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.